TG Therapeutics (NASDAQ:TGTX) Raised to “Buy” at Wall Street Zen

TG Therapeutics (NASDAQ:TGTX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other brokerages have also issued reports on TGTX. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st. B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, November 4th. Finally, Zacks Research upgraded TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Read Our Latest Report on TGTX

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $64.51 on Friday. The stock’s 50 day moving average price is $56.69 and its 200 day moving average price is $45.33. The firm has a market capitalization of $9.75 billion, a PE ratio of 97.74, a price-to-earnings-growth ratio of 5.08 and a beta of 1.89. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.75 and a current ratio of 4.50. TG Therapeutics has a one year low of $26.76 and a one year high of $68.03.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The firm had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The business’s quarterly revenue was up 60.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.43 EPS. As a group, sell-side analysts expect that TG Therapeutics will post 1.10 EPS for the current fiscal year.

Insider Activity

In other news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the transaction, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 8.87% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Entropy Technologies LP boosted its position in TG Therapeutics by 99.6% during the 3rd quarter. Entropy Technologies LP now owns 27,017 shares of the biopharmaceutical company’s stock valued at $1,507,000 after purchasing an additional 13,480 shares during the period. Jump Financial LLC grew its position in shares of TG Therapeutics by 241.0% during the third quarter. Jump Financial LLC now owns 26,709 shares of the biopharmaceutical company’s stock worth $1,490,000 after acquiring an additional 18,877 shares during the last quarter. Apis Capital Advisors LLC bought a new position in TG Therapeutics in the 3rd quarter worth about $11,825,000. Pathstone Holdings LLC increased its stake in shares of TG Therapeutics by 6.9% in the third quarter. Pathstone Holdings LLC now owns 9,014 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 584 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of TG Therapeutics by 318.0% in the third quarter. Marshall Wace LLP now owns 24,070 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 18,312 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

(Get Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

See Also

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.